

- the CDK9/cyclin T complex. *AIDS* 21: 575-582, 2007.
40. Tee, K. K., Li, X-J., Nohtomi, K., Ng, K. P., Kamarulzaman, A., and Takebe, Y. Identification of a novel circulating recombinant form (CRF33_01B) disseminating widely among various risk populations in Kuala Lumpur, Malaysia. *J. AIDS* 43(5): 523-9, 2006.
 41. Murakami, Y., Yamagoe, S. Noguchi, K., Takebe, Y., Uehara, Y. and Fukazawa, H. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by Latency-associated nuclear antigen of Kaposi ' s sarcoma-associated herpesvirus through interaction with Daxx. *J. Biol. Chem.* 281(38): 28113-28121, 2006.
 42. Takebe, Y. and Telesnitsky, A. Evidence for the acquisition of multidrug resistance by an HIV clinical isolate *via* human sequence transduction. *Virology* 351: 1-6, 2006.
 43. Naito, Y., Ui-Tei, K., Nishikawa, T., Takebe, Y., Saigo, K. siVirus: web-based antiviral siRNA design software for highly divergent viral sequences. *Nucl. Acid Res.* (Web Server issue) W448-W450, 2006.
 44. Dansako H, Ikeda M, Kato N. Limited suppression of the interferon-beta production by hepatitis C virus serine protease in cultured human hepatocytes. *FEBS J.* 274:4161-4176 (2007).
 45. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-HCV reagents: suppression of HCV replication by statins and synergistic action with interferon. *J Pharmacol Sci.* 105:145-150 (2007).
 46. Ikeda M, Kato N. Modulation of host metabolism as a target of new antivirals. *Adv. Drug Deliv. Rev.* 59:1277-1289 (2007).
 47. Peng LF, Kim SS, Matchacheep S, Lei X, Su S, Lin W, Runguphan W, Choe WH, Sakamoto N, Ikeda M, Kato N, Beeler AB, Porco JA Jr, Schreiber SL, Chung RT: Identification of Novel Epoxide Inhibitors of HCV Replication Using a High-Throughput Screen. *Antimicrob. Agents Chemother.*, 51(101):3756-3759 (2007)
 48. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Kato N. DDX3 DEAD box RNA helicase is required for hepatitis C virus (HCV) RNA replication. *J. Virol.* 81:13922-13926 (2007).
 49. Yano M, Ikeda M, Abe K, H. Dansako H., Ohkoshi S, Aoyagi, Y, Kato N. Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture. *Antimicrob. Agents Chemother.* 51: 2016-2027 (2007).
 50. Abe K, Ikeda M, Ariumi Y, Dansako H, Kato N. Serum-free cell culture system supplemented with lipid-rich albumin for hepatitis C virus (strain O of genotype 1b) replication. *Virus Res.* 125:162- 168 (2007).
 51. Abe K, Ikeda M, Dansako H, Naka K, Kato N. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. *Virus Res.* 125: 88-97 (2007).
 52. Kanada A, Takehara T, Ohkawa K, Tatsumi T, Sakamori R, Yamaguchi S, Uemura A, Kohga K, Sasakawa A, Hikita H, Hijioka T, Katayama K, Deguchi M, Kagita M, Kanto T, Hiramatsu N, Hayashi N. Type B Fulminant Hepatitis Is Closely Associated with a Highly Mutated Hepatitis B Virus Strain. *Intervirology* 50:349-401, 2007.
 53. Kurashige N, Hiramatsu N, Ohkawa K, Oze T, Inoue Y, Kurokawa M, Yakushijin T, Igura T, Kiso S, Kanto T, Takehara T, Tamura S, Kasahara A, Oshita M, Hijioka T, Katayama K, Yoshihara H, Hayashi E, Imai Y, Kato M, Hayashi N. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. *Hepato Res* (in press).
 54. Yu X, Qiao M, Atanasov I, Hu Z, Kato T, Liang TJ, Zhou ZH. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. *Virology* 2007 367:126-34.

55. Date T, Miyamoto M, Kato T, Morikawa K, Murayama A, Akazawa D, Tanabe J, Sone S, Mizokami M, Wakita T. An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain. *Hepato Res*. 2007 37(6):433-43.
56. Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, Wakita T, Liang TJ. Production of infectious hepatitis C virus of various genotypes in cell cultures. *J Virol*. 2007 81(9):4405-11.
57. Kondo Y, Machida K, Liu HM, Ueno Y, Kobayashi K, Wakita T, Shimosegawa T, Lai MM. Hepatitis C Virus Infection of T Cells Inhibits Proliferation and Enhances Fas-Mediated Apoptosis by Down-Regulating the Expression of CD44 Splicing Variant 6. *J Infect Dis*. 2009 199(5):726-736.
58. Suzuki R, Moriishi K, Fukuda K, Shirakura M, Ishii K, Shoji I, Wakita T, Miyamura T, Matsuura Y, Suzuki T. Proteasomal Turnover of Hepatitis C Virus Core Protein Is Regulated by Two Distinct Mechanisms: a Ubiquitin-Dependent Mechanism and a Ubiquitin-Independent but PA28{gamma}-Dependent Mechanism. *J Virol*. 2009 83(5):2389-2392.
59. Nitahara-Kasahara Y, Fukasawa M, Shinkai-Ouchi F, Sato S, Suzuki T, Murakami K, Wakita T, Hanada K, Miyamura T, Nishijima M. Cellular vimentin content regulates the protein level of hepatitis C virus core protein and the hepatitis C virus production in cultured cells. *Virology*. 2009 383(2):319-27.
60. Wakita T. Isolation of JFH-1 strain and development of an HCV infection system. *Methods Mol Biol*. 2009;510:305-27.
61. Akazawa D, Date T, Morikawa K, Murayama A, Omi N, Takahashi H, Nakamura N, Ishii K, Suzuki T, Mizokami M, Mochizuki H, Wakita T. Characterization of infectious hepatitis C virus from liver-derived cell lines. *Biochem Biophys Res Commun*. 2008 377(3):747-51.
62. Lan L, Gorke S, Rau SJ, Zeisel MB, Hildt E, Himmelsbach K, Carvajal-Yepes M, Huber R, Wakita T, Schmitt-Graeff A, Royer C, Blum HE, Fischer R, Baumert TF. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. *J Immunol*. 2008 181(7):4926-35.
63. Kimura T, Imamura M, Hiraga N, Hatakeyama T, Miki D, Noguchi C, Mori N, Tsuge M, Takahashi S, Fujimoto Y, Iwao E, Ochi H, Abe H, Maekawa T, Arataki K, Tateno C, Yoshizato K, Wakita T, Okamoto T, Matsuura Y, Chayama K. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. *J Gen Virol*. 2008 89(9):2108-13.
64. Kato T, Choi Y, Elmowalid G, Sapp RK, Barth H, Furusaka A, Mishiro S, Wakita T, Krawczynski K, Liang TJ. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. *Hepatology*. 2008 48(3):732-40.
65. Sir D, Chen WL, Choi J, Wakita T, Yen TS, Ou JH. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. *Hepatology*. 2008 48(4):1054-61.
66. Murakami K, Kimura T, Osaki M, Ishii K, Miyamura T, Suzuki T, Wakita T, Shoji I. Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. *J Gen Virol*. 2008 89(7):1587-92.
67. Ebihara T, Shingai M, Matsumoto M, Wakita T, Seya T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. *Hepatology*. 2008 48(1):48-58.
68. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T. Interaction of hepatitis C virus nonstructural protein 5A

- with core protein is critical for the production of infectious virus particles. *J Virol.* 2008 82(16):7964-76.
69. Mateu G, Donis RO, Wakita T, Bukh J, Grakoui A. Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. *Virology.* 2008 376(2):397-407.
70. Ishii K, Murakami K, Hmwe SS, Zhang B, Li J, Shirakura M, Morikawa K, Suzuki R, Miyamura T, Wakita T, Suzuki T. Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. *Biochem Biophys Res Commun.* 2008 371(3):446-50.
71. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. *Hepatology.* 2008 47(5):1437-45.
72. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. *J Virol.* 2008 82(12):5715-24.
73. HH Aly, K Shimotohno, M Hijikata: 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV. *BBRC*, 379: 330-334, 2009
74. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M. Direct Cytopathic Effects of Particular Hepatitis B Virus Genotypes in uPA/SCID Mouse with Human Hepatocytes. *Gastroenterology.* 2009. 136(2):652-662.
75. Kurbanov F, Tanaka Y, Kramvis A, Simmonds P, Mizokami M. When should "I" consider a new hepatitis B virus genotype? *J Virol.* 2008. 82(16):8241-8242.
76. Tanaka Y, Sanchez LV, Sugiyama M, Sakamoto T, Kurbanov F, Tatematsu K, Roman S, Takahashi S, Shirai T, Panduro A, Mizokami M. Characteristics of hepatitis B virus genotype G coinfecting with genotype H in Chimeric Mice Carrying Human Hepatocytes. *Virology.* 2008. 376(2):408-415.
77. Mori, Y., K. Moriishi, and Y. Matsuura. 2008. Hepatitis C virus core protein: its coordinate roles with PA28gamma in metabolic abnormality and carcinogenicity in the liver. *Int. J. Biochem. Cell Biol.* 40:1437-1442.
78. Okamoto, K., Y. Mori, Y. Komoda, T. Okamoto, M. Okochi, M. Takeda, T. Suzuki, K. Moriishi, and Y. Matsuura. 2008. Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. *J. Virol.* 82:8349-8361.
79. Okamoto, T., H. Omori, Y. Kaname, T. Abe, Y. Nishimura, T. Suzuki, T. Miyamura, T. Yoshimori, K. Moriishi, and Y. Matsuura. 2008. A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. *J. Virol.* 82:3480-3489.
80. Taguwa, S., T. Okamoto, T. Abe, Y. Mori, T. Suzuki, K. Moriishi, and Y. Matsuura. 2008. Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication. *J. Virol.* 82:2631-2641.
81. M. Sugaya, R. Saito, Y. Matsumura, K. Harada and A. Katoh "A facile method for the detection of specific RNA-polypeptide interactions using MULDI-Tof MS spectrometry" *J. Peptide Science*, 14: 978-983 (2008).
82. M. Sugaya, N. Nishino, A. Katoh and K. Harada "Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA " *J. Peptide Science*, 14: 924-935 (2008).
83. M. Sugaya, F. Nishimura, A. Katoh and K. Harada "Tailoring the peptide-binding specificity of an RNA by combinations of specificity-altering mutations" *Nucleosides*,

- Nucleotides, and Nucleic Acids*, 27: 534-545 (2008).
84. K. Harada, M. Sugaya, F. Nishimura, A. Katoh "Manipulation of the peptide-binding specificity of an RNA in a rational manner by combinations of specificity-altering mutations" *Nucleic Acids Symposium Series*, 52, 13-14 (2008)
 85. S. Horiya, C. - S. Koh, S. Matsufuji, and K. Harada "Analysis of the interaction between selected RNA-binding peptides and a target RNA containing a bulge and a GNRA-type tetraloop" *Nucleic Acids Symposium Series*, 52, 209-210 (2008)
 86. S. Machida, K. Usuba, M. A. Blaskovich, A. Yano, K. Harada, S. M. Sebt, N. Kato, and J. Ohkanda "Module Assembly for Protein Surface Recognition: Bivalent Type-I Geranylgeranyltransferase Inhibitors for Simultaneous Targeting of Interior and Exterior Protein Surfaces" *Chemistry*, 14, 1392-1401 (2008).
 87. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. *Hepatology*. 2008 Nov 19.
 88. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. *Gastroenterology*. 2009 136(3):1012-24.
 89. Sakai Y, Honda M, Fujinaga H, Tatsumi I, Mizukoshi E, Nakamoto Y, Kaneko S. Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. *Cancer Res*. 2008 68(24):10267-79.
 90. Minagawa H, Yamashita T, Honda M, Tabuse Y, Kamijo K, Tsugita A, Kaneko S. Comparative analysis of proteome and transcriptome in human hepatocellular carcinoma using 2D-DIGE and SAGE. *Protein J*. 2008 Dec;27(7-8):409-19.
 91. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T, Kaneko S. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. *J Hepatol*. 2009 50(1):100-10.
 92. Yamashita T, Honda M, Kaneko S. Application of Serial Analysis of Gene Expression in cancer research. *Curr Pharm Biotechnol*. 2008 9(5):375-82. Review.
 93. Mizukoshi E, Honda M, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. *J Hepatol*. 2008 49(6):946-54.
 94. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y, Kaneko S. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. *J Hepatol*. 2008 49(2):207-16.
 95. Minagawa H, Honda M, Miyazaki K, Tabuse Y, Teramoto R, Yamashita T, Nishino R, Takatori H, Ueda T, Kamijo K, Kaneko S. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. *BBRC*. 2008 366(1):186-92.
 96. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, Shimizu A, Kurita S, Takeshita Y, Ando H, Honda M, Kaneko S. Obesity Upregulates Genes Involved in Oxidative Phosphorylation in Livers of Diabetic Patients. *Obesity (Silver Spring)*. 2008 Oct 9.
 97. AW. Tai, Y Benita, LF. Peng, S-S Kim, N Sakamoto, RJ. Xavier, RT. Chung: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. *Cell Host & Microbe*, in press.

98. Onizawa, Kanai T, Totsuka T, Okamoto R, Tsuchiya K, Nemoto Y, Nagaishi T, Sakamoto N, Watanabe M: Signaling pathway via TNF α /NF κ B in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. *Am J Physiol Gastrointest Liver Physiol* in press.
99. S Toma, T Yamashiro, S Arakaki, J Shiroma, T Maeshiro, K Hibiya, N Sakamoto, F Kinjo, M Tateyama, J Fujita: Synergistic inhibition of intracellular hepatitis C virus replication by nelfinavir and interferon- α . *J Viral Hepatitis*, in press.
100. Fujii T, Kanai T, Tomita T, Nemoto Y, Totsuka T, Sakamoto N, Nakamura T, Tsuchiya K, Okamoto R, Watanabe M: FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow. *Eur J Immunol*, 38(12):3290-3303.
101. Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Chen CH, Suda G, Mishima K, Onuki Y, Yamamoto M, Maekawa S, Enomoto N, Kanai T, Tsuchiya K, Watanabe M: Two flavonoids extracts from a herb, Glycyrrhizae radix, inhibit in-vitro hepatitis C virus replication. *Hepatology Res* 2009; 39(1):60-69.
102. Sakamoto N, Tanabe Y, Yokota T, Saito K, Sekine-Osajima Y, Nakagawa M, Itsui Y, Tasaka M, Sakurai Y, Chen CH, Yano M, Ohkoshi S, Aoyagi Y, Maekawa S, Enomoto N, Kohara M, Watanabe M: Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. *J Gastro Hepatol* 2008; 23 (9) :1437-1447.
103. Nanmoku K, Imaizumi R, Tojimbara T, Nakajima I, Fuchinoue S, Sakamoto N, Watanabe M, Teraoka S: Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. *Transplant Proc* 2008; 40 (7):2382-2385.
104. Jin H, Yamashita A, Maekawa S, Yang P, He L, Takayanagi S, Wakita T, Sakamoto N, Enomoto N, Ito M: Griseofulvin, an oral antifungal agent, suppresses HCV replication in vitro. *Hepatology Res* 2008; 38(9):909-918.
105. Tomita T, Kanai T, Fujii T, Nemoto Y, Okamoto R, Tsuchiya K, Totsuka T, Sakamoto N, Watanabe M: Continuous generation of colitogenic CD4+ T cells may be one of the mechanisms to persist colitis. *Eur J Immunol* 2008; 38(5):1264-1274.
106. Tomita T, Kanai T, Fujii T, Nemoto Y, Okamoto R, Tsuchiya K, Totsuka T, Sakamoto N, Akira S, Watanabe M: MyD88-dependent Pathway in T Cells Directly Modulates the Expansion of Colitogenic CD4+ T Cells in Chronic Colitis, *J Immunol* 2008; 180(8):5291-5299.
107. Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Tasaka M, Sakamoto N, Miyake S: Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. *Gastroenterology* 2008; 134(5):1396-1405.
108. Totsuka T, Kanai T, Nemoto Y, Tomita T, Tsuchiya K, Sakamoto N, Okamoto R, Watanabe M: Immunosenescent colitogenic CD4+ T cells convert to regulatory cells and suppress colitis. *Eur J Immunol* 2008 2008; 38(5):1275-1286.
109. Aragaki M, Tsuchiya K, Okamoto R, Yoshioka S, Nakamura T, Sakamoto N, Kanai T, Watanabe M: Proteasomal degradation of Atoh1 by aberrant Wnt signaling maintains the undifferentiated state of colon cancer. *Biochem Biophys Res Commun* 2008; 368(4):923-929.
110. Amemiya F, Maekawa S, Itakura Y, Kanayama A, Takano S, Yamaguchi T, Itakura J, Kitamura T, Inoue T, Sakamoto M, Yamauchi K, Okada S, Sakamoto N, Enomoto N: Targeting lipid metabolism in the treatment of hepatitis C. *J Infect Dis* 2008; 197(3):361-370.

111. Kondo M, Sudo K, Tanaka R, Sano T, Sagara H, Iwamuro S, Takebe Y, Imai M, Kato S. Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR. *J Virol Methods*. 2009 Jan 3. [Epub ahead of print]
112. Tee KK, Takebe Y, Kamarulzaman A. Emerging and re-emerging viruses in Malaysia, 1997-2007. *Int J Infect Dis*. 2008 Nov 13. [Epub ahead of print]
113. Xia, X., Lu, L., Tee, K. K., Zhao, W., Wu, J., Yu, J., Li, X., Lin, Y., Mukhtar, MM., Hagedorn, CH., Takebe, Y. (2008). The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. *J. Med Virol*. 80 (7): 1142-52.
114. Tee, K. K., Pybus, OG., X-J, Li., Han, X., Shang, H., Kamarulzaman, A., Takebe, Y. (2008). Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. *J. Virol* 82: 9206-9215.
115. Shimizu, N., Tanaka, A., Mori, T., Ohtsuki, T., Hoque, A., Jinno-Oue, A., Apichartpiyakul, C., Kusagawa, S., Takebe, Y., Hoshino, H. (2008). A formylpeptide receptor, FPRL1, acts as an efficient coreceptor for primary isolates of human immunodeficiency virus. *Retrovirology* 5: 52
116. Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn CH, Takebe Y. (2008). The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. *J Med Virol*. 2008 Jul;80(7):1142-52.
117. Liu P, Xiang K, Tang H, Zhang W, Wang X, Tong X, Takebe Y, Yang R. (2008). Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. *AIDS Res Hum Retroviruses*. 2008 Jan;24(1):1-6.
118. Louisirirochanakul S, Sutthent R, Wasi C, Chuenchitra T, Nitayaphan S, Brown AE, Polonis VR, Nakayama EE, Shioda T, Liu H, Takebe Y. (2008). Host genetic analysis of HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. *AIDS Res Hum Retroviruses*. 2007 Dec;23(12):1605-8.
119. Tee, K. K., Pybus, OG., Liao, H., Uenishi, R., Hase, S., Kamarulzaman, A., Li, X-J., and Takebe, Y. (2008). Chronology of the HIV-1 CRF07_BC expansion in East-Asia. *AIDS* 22: 156-158, 2008.
120. Takebe, Y. Uenishi, R., and Li. X-J. (2008). Global molecular epidemiology of HIV: Understanding the genesis of AIDS pandemic. "HIV-1: Molecular biology and pathogenesis" (ed. Kuan Teh Jeang). *Advances in Pharmacology* vol. 56: 1-25, 2008.
121. G. Nishimura, M Ikeda, K. Mori, T. Nakazawa, Y. Ariumi, H. Dansako and N. Kato. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to ant-HCV reagents. *Antiviral Res.* In press (2009).
122. N. Kato, K. Abe, K. Mori, Y. Ariumi, H. Dansako, T. Wakita, and M. Ikeda. Genetic variability and diversity of intracellular genome-length hepatitis C virus RNA in long-term cell culture. *Arch Virol*. 154, 77-85(2009).
123. M. Kuroki, Y. Ariumi, M. Ikeda, H. Dansako, T. Wakita, and N. Kato. Arsenic trioxide inhibits HCV RNA replication through modulation of the glutathione redox system and oxidative stress. *J. Virol*. 83, 2338-2348 (2009).
124. Y. Ariumi, M. Kuroki, H. Dansako, K. Abe, M. Ikeda, T. Wakita, and N. Kato: ATM, a DNA damage sensor, is required for hepatitis C virus RNA replication. *J. Virol*. 82, 9639-9646(2008).
125. H. Dansako, M. Ikeda, K. Abe, K. Mori, K. Takemoto, Y. Ariumi, and N. Kato: A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication. *Virus Res*. 137, 72-79(2008)
126. K. Mori, K. Abe, H. Dansako, Y. Ariumi, M.

- Ikeda, and N. Kato. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. *Biochem Biophys Res Commun.* 371, 104-109(2008).
127. K. Hirano, T. Ichikawa, K. Nakao, A. Matsumoto, H. Miyaaki, H. Shibata, S. Eguchi, M. Takatsuki, M. Ikeda, H. Yamasaki, N. Kato, T. Kanematsu, N. Ishii, K. Eguchi. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin A, on interferon-induced antiviral protein in human hepatocyte cells. *Liver. Transpl.*, 14:292-8 (2008).
128. M. Nakamura, H. Saito, M. Ikeda, S. Tada, N. Kumagai, N. Kato, K. Shimotohno, T. Hibi. Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. *J. Med. Virol.*, 80:632-639 (2008).
129. M. Ando, M. Korenaga, K. Hino, M. Ikeda, N. Kato, S. Nishida, I. Hidaka, I. Sakaida. Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication *Liver Int.* 28:1158-66 (2008)
130. Kurashige N, Hiramatsu N, Ohkawa K, Oze T, Inoue Y, Kurokawa M, Yakushijin T, Igura T, Kiso S, Kanto T, Takehara T, Tamura S, Kasahara A, Oshita M, Hijioka T, Katayama K, Yoshihara H, Hayashi E, Imai Y, Kato M, Hayashi N. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. *Hepatol Res* 38: 450-456, 2008.
131. Kanada A, Takehara T, Ohkawa K, Kato M, Tatsumi T, Miyagi T, Sakamori R, Yamaguchi S, Uemura A, Kohga K, Sasakawa A, Hikita H, Kawamura K, Kanto T, Hiramatsu N, Hayashi N. Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection. *Hepatol Res* 38: 622-628, 2008.
132. Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Supportive role of precore and preS2 genomic changes on establishment of lamivudine-resistance hepatitis B virus. *J Infect Dis* 198: 1150-1158, 2008.
133. Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. *J Med Virol* (in press)
134. Hussein H. Aly, Yue Qi, Kimie Atsuzawa, Noobuteru Usuda, Yasutsugu Takada, Yasuhito Tanaka, Masashi Mizogami. Kunitada Shimotohno, Makoto Hijikata: Strain-dependent viral dynamics and virus cell interactions observed in a novel in vitro system supporting the life cycle of blood borne HCV. *Hepatology*, 50(3), 689-696, 2009
135. Hussein H. Aly, Kunitada Shimotohno, Makoto Hijikata: 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV. *Biochem. Biophys. Res. Commun.*, 379: 330-334, 2009
136. Takayuki Murata, Yoshitaka Sato, Sanae Nakayama, Ayumi Kudoh, Satoko Iwahori, Hiroki Isomura, Masako Tajima, Takayuki Hishiki, Takayuki Ohshima, Makoto Hijikata, Kunitada Shimotohno, and Tatsuya Tsurumi: TORC 2, a coactivator of CREB, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein, *J. Biol. Chem.* 284, 8033-8041, 2009
137. Kazuo Sugiyama, Kenji Suzuki, Takahide Nakazawa, Kenji Funami, Takayuki Hishiki, Kazuya Ogawa, Satoru Saito, Kumiko W. Shimotohno, Takeshi Suzuki, Yuko Shimizu, Seiri Tobita, Makoto Hijikata, Hiroshi Takaku,

- Kunitada Shimotohno: Genetic analysis of hepatitis C virus with defective genome and its infectivity in vitro. *J. Virol.*, 83(13), 6922-6928, 2009.
138. Kaku Goto, Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kunitada Shimotohno: Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. *Cancer Science*, 100 (10), 1943-1950, 2009.
139. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. *Hepatol Res.* 2010. 40(1):14-30.
140. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *J Virol.* 2009. 83(20):10538-47.
141. Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, Isoda N, Kang JH, Sumino Y, Yatsushashi H, Takikawa Y, Kaneko S, Yamada G, Karino Y, Tanaka E, Kato J, Sakaida I, Izumi N, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. Case-control study for the identification of virological factors associated with fulminant hepatitis B. *Hepatol Res.* 2009. 39(7):648-56.
142. Taguwa, S., H. Kambara, H. Omori, H. Tani, T. Abe, Y. Mori, T. Suzuki, T. Yoshimori, K. Moriishi, and Y. Matsuura. Cochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway. *J. Virol.* 83:10427-10436. 2009.
143. Moriya, K., H. Miyoshi, T. Tsutsumi, S. Shinzawa, H. Fujie, Y. Shintani, H. Yotsuyanagi, K. Moriishi, Y. Matsuura, T. Suzuki, T. Miyamura, and K. Koike. Tacrolimus Ameliorates Metabolic Disturbance and Oxidative Stress Caused by Hepatitis C Virus Core Protein. Analysis Using Mouse Model and Cultured Cells. *Am. J. Pathol.* 175:1515-1524. 2009
144. Kukihara, H., K. Moriishi, S. Taguwa, H. Tani, T. Abe, Y. Mori, T. Suzuki, T. Fukuhara, A. Taketomi, Y. Maehara, and Y. Matsuura. Human VAP-C negatively regulates hepatitis C virus propagation. *J. Virol.* 83:7959-7969. 2009
145. Hodo Y, Hashimoto SI, Honda M, Yamashita T, Suzuki Y, Sugano S, Kaneko S, Matsushima K. Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. *Genomics.* 2010 Jan 21. [Epub ahead of print]
146. Takatori H, Yamashita T, Honda M, Nishino R, Arai K, Yamashita T, Takamura H, Ohta T, Zen Y, Kaneko S. dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma. *Liver Int.* 2009 Nov 30. [Epub ahead of print]
147. Komura T, Sakai Y, Honda M, Takamura T, Matsushima K, Kaneko S. CD14+monocytes are vulnerable and functionally impaired under ER stress in patients with type 2 diabetes. *Diabetes.* 2009 Dec 3. [Epub ahead of print]
148. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. *Hepatology.* 2009 49(4):1098-112
149. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. *Gastroenterology.* 2009 136(3):1012-24.
150. Ootsuji H, Honda H, Kaneko S, Usui S, Okajima M, Okada H, Sakai Y, Takamura T, Horimoto K, Takamura M. Altered Hepatic Gene Expression Profiles Associated with Myocardial Ischemia. *Circ Cardiovasc Genet.* 2010 Feb 1;3(1):68-77.
151. Shirasaki T, Honda M, Mizuno H, Shimakami T,

- Okada H, Sakai Y, Murakami S, Wakita Tand Kaneko S. La protein required for IRES-directed translation is a potential therapeutic target for hepatitis C virus replication. *Journal of Infectious Diseases* 2010 in press
152. M. Zahed, T. Suzuki, A. Suganami, H. Sugiyama, K. Harada, M. Takiguchi, Y. Tamura, N. Suzuki "Screening of SMG7-binding peptides by combination of phage display and docking simulation analysis" *Protein & Peptide Letters*, 16, 301-305 (2009)
153. Horiya, M. Inaba, C-S. Kou, H. Uehara, N. Masui, M. Mizuguchi, M. Ishibashi, S. Matsufuji and K. Harada* "Replacement of the I boxB RNA-N peptide with heterologous RNA-peptide interactions relaxes the strict spacial requirements for the formation of a transcription antitermination complex" *Molecular Microbiology*, 74, 85-97 (2009)
154. A. Yano, S. Horiya, T. Minami, E. Haneda, M. Ikeda, and K. Harada "Identification of antisense RNA stem-loops that inhibit RNA-protein interactions using a bacterial reporter system" *Nucleic Acids Research*, Feb. 15 (Epub ahead of print) (2010)
155. KK, Kook H Kim, HY Kim, HK Cho, N Sakamoto, JH Cheong: Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway. *FEBS Letter* 2010; *Epub*
156. M Nakagawa, N Sakamoto, M Ueyama, K Mogushi, S Nagaie, Y Itsui, S Azuma, S Kakinuma, H Tanaka, N Enomoto, M Watanabe: Mutations in the Interferon Sensitivity Determining Region and virological response to combination therapy with Pegylated-interferon alpha2b plus ribavirin in patients with chronic hepatitis C-1b infection. *J Gastroenterol*, in press
157. Y Nishimura-Sakurai, N Sakamoto, K Mogushi, S Nagaie, M Nakagawa, Y Itsui, et al.: Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. *J Gastroenterol Epub*
158. T Mizui, S Yamashina, I Tanida, M Takashima, Y Takei, T Ueno, N Sakamoto, K Ikejima, T Kitamura, N Enomoto, T Sakai, E Kominami, S Watanabe: Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. *J Gastroenterol, Epub*
159. Y Itsui, N Sakamoto, S Kakinuma, M Nakagawa, Y Sekine-Osajima, M Tasaka-Fujita, Y Nishimura-Sakurai, et al.: Antiviral effects of the interferon-induced protein GBP-1 and its interaction with the hepatitis C virus NS5B protein. *Hepatology* 2009; 50:1727-1737
160. Y Tanaka, N Nishida, M Sugiyama, M Kurosaki, K Matsuura, N Sakamoto, M Nakagawa, et al.: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nature Genetics* 2009; 41 (10):1105-1109
161. K Kim, KH Kim, E Ha, JY Park, N Sakamoto, JH Cheong: Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. *FEBS Letter* 2009;583 (17):2720-2726
162. Tomita T, Kanai T, Totsuka T, Nemoto Y, Okamoto R, Tsuchiya K, Sakamoto N, et al.: IL-7 Is Essential for Lymphopenia- driven Turnover of Colitogenic CD4+ Memory T Cells in Chronic Colitis. *Eur J Immunol* 2009;38 (10):2737-2747
163. Nemoto Y, Kanai T, Kameyama K, Shinohara T, Sakamoto N, et al.: Long-lived Colitogenic CD4+ Memory T Cells Residing Outside the Intestine Participate in the Perpetuation of Chronic Colitis. *J Immunol* 2009;183 (8):5059-5068
164. M Ohira, K Ishiyama, Y Tanaka, M Daskali, Y Igarashi, H Tashiro, N Hiraga, M Imamura, N Sakamoto, et al.: Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. *J Clin Invest.* 2009;119:3226-3235

165. S-Y Wang, C-P Tseng, K-C Tsai, C-F Lin, C-Y Wen, H-S Tsay, N Sakamoto, C-H Tseng, J-C Cheng: Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from *Lonicera hypoglauca* Miq. *Biochem Biophys Res Commun* 2009; 385(2):230-235
166. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, et al.: The isomerase active site of cyclophilin a is critical for HCV replication. *J Biol Chem* 2009; 284(25):16998-17005
167. T Totsuka, T Kanai, Y Nemoto, T Tomita, R Okamoto, K Tsuchiya, T Nakamura, N Sakamoto, et al.: RANK-RANKL signaling pathway is critically involved in the function of CD4+ CD25+ regulatory T cells in chronic colitis. *J Immunol* 2009; 182(19):6079-6087
168. S Toma, T Yamashiro, S Arakaki, J Shiroma, T Maeshiro, K Hibiya, N Sakamoto, et al.: Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon- α . *Journal of Viral Hepatitis* 2009; 16(7):506-512
169. Onizawa, Kanai T, Totsuka T, Okamoto R, Tsuchiya K, Nemoto Y, Nagaishi T, Sakamoto N, Watanabe M: Signaling pathway via TNF- α /NF- κ B in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. *Am J Physiol Gastrointest Liver Physiol* 2009; 296(4):G850-859
170. AW. Tai, Y Benita, LF. Peng, S-S Kim, N Sakamoto, RJ. Xavier, RT. Chung: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. *Cell Host Microbe* 2009; 5(3):298-307
171. Murayama M, Okamoto R, Tsuchiya K, Akiyama J, Nakamura T, Sakamoto N, et al.: Musashi-1 suppresses expression of Paneth cell-specific genes in human intestinal epithelial cells. *J Gastroenterol* 2009;44(3):173-82
172. Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. *J Med Virol* 81: 798-806, 2009
173. Ohkawa K, Takehara T, Ishida H, Kodama T, Shimizu S, Hikita H, Yamamoto M, Kohga K, Sasakawa A, Uemura A, Sakamori R, Yamaguchi S, Li W, Hosui A, Miyagi T, Tatsumi T, Katayama K, Hayashi N. Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion. *Biochem Biophys Res Commun* (in press)
174. Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimoto M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Yamasaki H, Ikeda M, Kato N, and Eguchi K. Interferon- α -induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. *J. Gastroenterol.* 44:856-863, 2009.
175. Kato N, Abe K, Mori K, Ariumi Y, Dansako H, and Ikeda M. Genetic variability and diversity of intracellular genome-length hepatitis C virus RNA in long-term cell culture. *Arch. Virol.* 154:77-85, 2009.
176. Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M, Kato N, Ide Y, Shoji I, Hotta H. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. *J Hepatol.* 50: 883-894 2009.
177. Kawai Y, Ikeda M, Abe K, Yano M, Ariumi Y, Dansako H, Yamamoto K, and Kato N. Development of an HCV relapse model using genome-length HCV RNA-harboring cells possessing the IFN- α -resistance phenotype. *Hepatol. Res.*, 39:898-909, 2009.
178. Ikeda M, Mori K, Ariumi Y, Dansako H, and Kato N. Oncostatin M synergistically inhibits HCV RNA replication in combination with

- interferon- α . *FEBS Letters*, 583:1434-1438, 2009.
179. Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, Mori K, Dansako H, Ariumi Y, Ohkoshi S, Aoyagi Y, and Kato N. Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. *Hepatology*, 50:678-688, 2009.
180. Kato N, Mori K, Abe K, Dansako H, Kuroki M, Ariumi Y, Wakita T, and Ikeda M. Efficient replication systems for hepatitis C virus using a new hepatoma cell line. *Virus Res.*, 146:41-50, 2009.
181. Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, Miura S. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. *World J Gastroenterol.*, in press, 2010
182. Tanaka, N., Mamemura, T., Abe, S., Imabayashi, K., Kashiwada, Y., Takaishi, Y., Suzuki, T., Takebe, Y., Kubota, T., and Kobayashi, J. (2009). Bixoxanthones A-D, prenylated xanthones from roots of hypericum chinense. (in press)
183. Hassan, R., Suzu, S., Hiyoshi, M., Takahashi-Makise, N., Ueno, T., Agatsuma, T., Akari, H., Komano, J., Takebe, Y., Motoyoshi, K., Okada, S. (2009). Dys-regulated activation of a src tyrosine kinase Hck at the golgi disturbs N-glycosylation of a cytokine receptor Fms. *J Cell Physiol.* 221(2): 458-468.
184. Delviks-Frankenberry, KA., Nikolenko, GN., Maldarelli, F., Hase, S., Takebe, Y., Pathak, VK. (2009). Subtype-specific differences in the HIV-1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3' -azido-3' -deoxythymidine. *J. Virol.* 83(17): 8502-8513.
185. Tanaka, R., Tsujii, H., Yamada, T., Kajimoto T., Amano, F., Hasegawa, J., Hamashima Y., Node, M., Katoh, K., Takebe, Y. (2009). Novel 3 α -methoxyserrat-14-en-21 β -ol (PJ-1) and 3 β -methoxyserrat-14-en-21 β -ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents. *Bioorg Med. Chem.* 17(14): 5238-46.
186. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Foster TP, Kousoulas G, Wakita T, Dash S. Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. *Virol J.* 2010 7(1):36.
187. Ishibashi M, Wakita T, Esumi M. 2',5'-Oligoadenylate synthetase-like gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro. *Biochem Biophys Res Commun.* 2010 392(3):397-402.
188. Hmwe SS, Aizaki H, Date T, Murakami K, Ishii K, Miyamura T, Koike K, Wakita T, Suzuki T. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin. *Antiviral Res.* 2010 85(3):520-524.
189. Angus AG, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, Adair R, Graham S, Owsianka AM, Targett-Adams P, Li K, Wakita T, McLauchlan J, Lemon SM, Patel AH. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. *J Gen Virol.* 2010 91(1):122-32..
190. Seronello S, Ito C, Wakita T, Choi J. Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD⁺. *J Biol Chem.* 2010, 285(2):845-54.
191. Abe K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. *Arch Virol.* 2009;154(10):1671-7.
192. Saeed M, Suzuki R, Kondo M, Aizaki H, Kato T, Mizuochi T, Wakita T, Watanabe H, Suzuki T. Evaluation of hepatitis C virus core antigen assays in detecting recombinant viral antigens of various genotypes. *J Clin Microbiol.* 2009 Dec;47(12):4141-3.

193. Murakami Y, Noguchi K, Yamagoe S, Suzuki T, Wakita T, Fukazawa H. Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR. *Antiviral Res.* 2009 83(2):112-7.
194. Dansako H, Ikeda M, Ariumi Y, Wakita T, Kato N. Double-stranded RNA-induced interferon-beta and inflammatory cytokine production modulated by hepatitis C virus serine proteases derived from patients with hepatic diseases. *Arch Virol.* 2009;154(5):801-10.
195. Weng L, Du J, Zhou J, Ding J, Wakita T, Kohara M, Toyoda T. Modification of hepatitis C virus 1b RNA polymerase to make a highly active JFH1-type polymerase by mutation of the thumb domain. *Arch Virol.* 2009;154(5):765-73.
196. Hara H, Aizaki H, Matsuda M, Shinkai-Ouchi F, Inoue Y, Murakami K, Shoji I, Kawakami H, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T. Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein. *J Virol.* 2009 83(10):5137-47.
197. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. *J Biol Chem.* 2009 284(14):9237-46.
198. 中川美奈, 坂本直哉: 小胞体ストレスによるシグナル伝達. *分子消化器病* 2007; 4(4):367-372.
199. 坂本直哉: C型慢性肝炎の進展と治療抵抗性: ウイルス変異の観点から. *日本内科学会雑誌* 2007; 97(1):64-68.
200. 中川美奈, 坂本直哉: C型肝炎ウイルスの構造と病態. *治療学* 2007 in press.
201. 長谷彩希, 草川茂, 武部豊. 逆転写酵素活性測定法-³²Pを用いた免疫不全ウイルス(HIV)のウイルス学的研究技術. 秀潤社: 細胞工学別冊 RIの逆襲; アイソトープを活用した簡単・安全バイオ実験. 127-131, 2007.
202. 武部豊. HIV サブタイプと感染経路. *治療.* 88(12): 2843-2851, 2006.
203. 土方 誠: HCVと肝発癌 *医学のあゆみ* 224(9), 693-698 2008
204. 宮成 悠介, 臼田 信光, 土方 誠, 下遠野 邦忠: C型肝炎ウイルスの生活環と発がん *化学と生物* 46(12) 826-831 2008
205. 土方 誠, アリ・ハッサン・フセイン, 下遠野 邦忠: 3D細胞培養系を用いた患者血液由来 HCV培養. *肝・胆・膵* 57(5), 679-687 2008
206. 坂本直哉: HCV増殖・培養系を用いた抗ウイルス化合物の同定. *医学のあゆみ* 2009 in press.
207. 坂本直哉, 横田隆徳: siRNAによるC型肝炎遺伝子治療. *バイオ医薬品の開発技術とシーズ* 2009 in press.
208. 坂本直哉: 抗ウイルス薬臨床試験の現況 overview. *肝胆膵* 2008 in press.
209. 村松正明, 坂本直哉, 斉藤貴史, 河田純男: C型肝炎の経過に影響を与える SNP 探索と創薬. *肝胆膵* 2008 in press.
210. 箆島裕子, 坂本直哉, 渡辺守: 細胞障害性 HCV: 肝胆膵 2008 in press.
211. 田坂めぐみ, 坂本直哉: HCVによる自然免疫系の抑制. *肝胆膵* 2008.
212. 坂本直哉: テラプレビル、すべてを解決する夢の新薬か. *Medical Practice* 2008; 25(19):1829-1832.
213. 井津井康浩, 坂本直哉, 渡辺守: C型肝炎ウイルスと肝細胞アポトーシスはどのようにかかわるのか? *分子消化器病* 2008; 5(2):163-169.
214. 武部 豊 (2009). エイズワクチンの開発動向: アデノウイルスワクチン国際臨床試験頓挫の波紋とその意味 (特集: 各医療機関における国際共同試験の取り組み) *PHARM STAGE* Vol. 8, No. 10: 1-6, 2009
215. 武部 豊, 上西理恵 (2008). HCV エントリー・粒子形成阻害剤: 新規クラス薬剤スクリーニング. *C型肝炎のすべて・2009 新規治療法*. *肝胆膵* 57(5): 1047-1056, 2008.
216. 武部 豊. 「エイズワクチン開発の最新動向」 Challenges to AIDS vaccine development *細胞*, Sept. 2008.
217. 武部 豊, 長谷彩希, 廖 華南, 上西理恵. (2008). アジアにおけるエイズ危機と日本: 危険水域に入った我が国. *感染・炎症・免疫* 2008 Vol. 38 (3): 182-193, 2008.

218. 廖華南、長谷彩希、上西理恵、武部 豊 (2008), エイズに対する新規治療薬の開発動向. Pharmastage ファームステージ 2008年8月号
219. 武部 豊, 山本直樹. 「エイズワクチン(メルク・アデノウイルスワクチン)・トライアルの失敗の意味すること」. 病原微生物検出情報 Infectious Agents Surveillance Report (IASR) [http://idsc.nih.go.jp/iasr/index-j.html] June, 2008.
220. 上西理恵, 長谷彩希, Liao Huanan, 武部豊. (2008). C型肝炎ウイルスに対する新規治療薬の開発動向. PHARM STAGE Vol.8, No.3: 1-5, 2008.

著書

1. 坂本直哉、横田隆徳: siRNAによるC型肝炎遺伝子治療. バイオ医薬品の開発技術とシーズ 2009年3月、シーエムシー出版 p246-251

総説

1. Sakamoto N, Wu GY: Prospects for future therapy of hepatitis C virus infection. *Future Virology* 2009; 4(5):453-462
2. Sakamoto N, Watanabe M: New therapeutic approaches to HCV. *J Gastroenterol* 2009; 44(7):643-649
3. 櫻井幸、坂本直哉、渡辺守: HCV増殖に関連する糖脂質代謝遺伝子ネットワーク. 肝胆膵 2009; 59(6):1163-1172
4. 坂本直哉: HCV増殖・培養系を用いた抗ウイルス化合物の同定. 医学のあゆみ 2009; 229(1):107-110
5. 上西理恵、長谷彩希、武部 豊. 肝炎治療薬. 「C型肝炎治療: 新規抗HCV薬の開発」46(2): 109-123. 特集・抗ウイルス薬物療法の現状と今後の展望 医薬ジャーナル社. 東京. 2010.
6. 武部 豊、上西理恵. HCVエントリー・粒子形成阻害剤: 新規クラス薬剤スクリーニング. 「C型肝炎のすべて 2009」新規治療法. 肝胆膵 57(5): 1047-1056, アークメディア社 2008

2. 学会発表および講演など

1. 脇田隆宇, 「C型肝炎のウイルス培養系の開発とその応用」、第43回肝形態科学研究会、ホ

- テルグランパシフィックメリディアン、(2007, 5.30)
2. 脇田隆宇, 「in vivo と in vitro における HCV 複製」、第4回ウイルス学キャンプ in 湯河原、ウエルシティ湯河原、(2007, 6.6-7)
3. 脇田隆宇, 「C型肝炎ウイルスの基礎研究」、第3回広島肝臓プロジェクト研究センターシンポジウム、広島大学廣仁会館、(2007, 6.29)
4. 脇田隆宇, 「C型肝炎ウイルスの感染増殖機構」、The 6th Hepatitis Expert Meeting、軽井沢プリンスホテル、(2007, 8.25)
5. 脇田隆宇, 「C型肝炎ウイルスの複製および増殖機構」、第27回名古屋肝炎セミナー 第116回名古屋肝疾患研究会、名古屋東急ホテル、(2007, 9.21)
6. 脇田隆宇, 「Infection and replication of hepatitis C virus」、アジア太平洋消化器病週間 Asian Pacific Digestive Week 2007 サテライトシンポジウム、神戸商工会議所会館、(2007, 10.17)
7. 脇田隆宇, 「基礎研究に基づくC型肝炎ウイルスの新規治療とワクチン開発」、第10回熊本ウイルス感染症研究会、熊本全日空ホテル、(2007, 10.26)
8. 脇田隆宇, 「C型肝炎ウイルスの基礎研究」、第22回臨床肝臓カンファレンス、日本海運倶楽部、(2007, 11.10)
9. 脇田隆宇, 「C型肝炎ウイルス基礎研究の進歩」、第167回高知肝疾患症例検討会、高知新阪急ホテル、(2007, 11.20)
10. 脇田隆宇, 「C型肝炎ウイルスの複製および粒子形成」、学術講演会第10回リサーチフォーラム「ウイルスとヒト」、芝蘭会館別館、(2007, 12.22)
11. 脇田隆宇, 「C型肝炎ウイルスに対するワクチン開発」第11回日本ワクチン学会学術集会、パシフィコ横浜、(2007, 12.8-9)
12. 今村道雄、平賀伸彦、木村俊之、畠山剛、柘植雅貴、野口千笑、高橋祥一、本多政夫、金子周一、脇田隆宇、茶山一彰、培養細胞および動物モデルを用いた肝炎ウイルスのインターフェロン感受性の検討、第43回日本肝臓学会総会、ホテルグランパシフィックメリディアン、(2007, 5.31-6.1)、ワークショップ1 「肝炎ウイルス研究の進歩」

13. 相崎英樹、原弘道、森川賢一、宮村達男、脇田隆宇、鈴木哲朗、脂質の C 型肝炎ウイルス感染、粒子形成における役割、第 4 3 回日本肝臓学会総会、ホテルグランパシフィックメリディアン、(2007, 5. 31-6. 1)、ワークショップ 1 「肝炎ウイルス研究の進歩」
14. 森川賢一、脇田隆宇、培養細胞で作製した感染性 C 型肝炎ウイルス (HCV) 粒子のワクチン開発への応用、第 4 3 回日本肝臓学会総会、ホテルグランパシフィックメリディアン、(2007, 5. 31-6. 1)、ワークショップ 1 「肝炎ウイルス研究の進歩」
15. 脇田隆宇、C 型肝炎ウイルスの感染および複製増殖機構、第 31 回阿蘇シンポジウム「ウイルスと戦う」、阿蘇プリンスホテル、(2007, 7. 27-28)
16. 有海康雄、黒木美沙緒、阿部健一、團迫浩方、池田正徳、脇田隆宇、トロノ ディディエ、加藤宣之、DNA 損傷センサー ATM と Chk2 は HCV の RNA 複製に必要な宿主因子である、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)、ワークショップ 6 ウイルスと癌
17. 政木隆博、鈴木亮介、松田麻未、松浦善治、宮村達男、脇田隆宇、鈴木哲朗、RNA polymerase I システムを用いた感染性 C 型肝炎ウイルス粒子の作成と抗ウイルス薬の薬効評価への応用、第 4 3 回日本肝臓学会総会、ホテルグランパシフィックメリディアン、(2007, 5. 31-6. 1)
18. 箴島裕子、坂本直哉、中川美奈、田坂めぐみ、櫻井幸、井津井康浩、陳正新、榎本信幸、脇田隆宇、渡辺守、plaque-forming assay を用いた細胞障害性 HCV の選択と機能解析、第 4 3 回日本肝臓学会総会、ホテルグランパシフィックメリディアン、(2007, 5. 31-6. 1)
19. 平賀伸彦、今村道雄、木村俊之、柘植雅貴、野口千笑、高橋祥一、本多政夫、金子周一、脇田隆宇、茶山一彰、リバーズジェネティクスにより作製した HCV 感染マウスを用いた genotype 別のインターフェロン感受性の検討、第 4 3 回日本肝臓学会総会、ホテルグランパシフィックメリディアン、(2007, 5. 31-6. 1)
20. 伊達朋子、村山麻子、赤澤大輔、森川賢一、石井孝司、野本明男、鈴木哲朗、脇田隆宇、遺伝子型 2a/2b 間でのキメラウイルスの作製および性状解析、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
21. 有海康雄、黒木美沙緒、阿部健一、團迫浩方、池田正徳、脇田隆宇、加藤宣之、HCV の RNA 複製に必要な宿主因子 DDX3 DEAD box RNA ヘリカーゼ、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
22. 村山麻子、伊達朋子、赤澤大輔、森川賢一、石井孝司、鈴木哲朗、脇田隆宇、HCV JFH-1 株の複製および感染性ウイルス粒子形成に重要な領域の解析、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
23. 下池貴志、Mckenna Sean, Lindhout Darrin, 脇田隆宇、Puglisi Joseph、HCV IRES は PKR を活性化するが、それによる翻訳は eIF2 のリン酸化耐性である、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
24. 阿部克俊、村上恭子、市村徹、高宮智史、大崎一直、鈴木哲朗、宮村達男、小池和彦、脇田隆宇、勝二郁夫、HCV コア蛋白と結合する新規宿主因子 hnRNP H1/H2 の同定と相互作用、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
25. 加藤孝宣、脇田隆宇、HCV JFH-1 株の in vivo での病原性の検討、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
26. 海老原敬、松本美佐子、脇田隆宇、瀬谷司、HCV 感染アポトーシス細胞を介した樹状細胞の成熟化、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
27. 上西理恵、納富香子、長谷彩希、鈴木哲朗、脇田隆宇、竹部豊、新規阻害剤探索のための HCV 感染・増殖アッセイ系の樹立とその評価、日本ウイルス学会第 5 5 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
28. 尾見法昭、赤澤大輔、高橋仁、森川賢一、伊達朋子、石井孝司、鈴木哲朗、脇田隆宇、細胞

- 培養により産生された HCV ウイルスの免疫原性に関する検討、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
29. 竹部豊, 上西理恵、納富香子、長谷彩希、鈴木哲朗, 脇田隆宇, 感染性 HCV クローン JFH-1 を用いた感染・増殖アッセイに基づくスクリーニングによる新規標的を持つ HCV 阻害剤の同定とその解析、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 30. 村上恭子, 勝二郁夫, 木村敬郎、鈴木哲朗, 宮村達男, 脇田隆宇, 血球系細胞に HCV JFH-1 株の感染および複製の検討、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 31. 赤澤大輔、伊達朋子、森川賢一、村山朝子、尾見法昭、高橋仁、白倉雅之、鈴木哲朗、脇田隆宇、肝細胞株における感染性 HCV 粒子の作製と性状解析、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 32. 高橋仁、尾見法昭、赤澤大輔、白倉雅之、鈴木哲朗、脇田隆宇、エピトープタグを付加した組換え HCV 粒子の作製と性状解析、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 33. 江角真理子、石橋真理子、清水洋子、森田奈央子、山口裕美、高山由理子、野本聡美、脇田隆宇、清水一史、L-SIGN 陽性細胞の C 型肝炎ウイルス感染感受性解析、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 34. 相崎英樹、原弘道、森川賢一、井上寧、谷英樹、松浦善治、斎藤恭子、深澤征義、花田賢太郎、マイケル・ライ、宮村達男、脇田隆宇、鈴木哲朗、C 型肝炎ウイルス脂質成分の感染における役割、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 35. 村上裕子、山越智、鈴木哲朗, 脇田隆宇, 深澤秀輔、培養細胞を用いた C 型肝炎ウイルス(HCV) の阻害剤のスクリーニング、日本ウイルス学会第 55 回学術集会、札幌コンベンションセンター(2007, 10. 21-23)
 36. 石橋真理子、清水洋子、山口裕美、高山由理子、野本聡美、脇田隆宇、清水一史、江角真理子、C 型肝炎ウイルス感染における肝臓類洞内皮 C 型レクチン (L-SIGN) の役割、第 30 回日本分子生物学会年会、パシフィコ横浜(2007, 12. 11-15)
 37. Munakata T, Wakita T, Nomoto A, Toll-like receptor 3 is a downstream target of Rb/E2F pathway activated by hepatitis C virus, 、第 30 回日本分子生物学会年会、パシフィコ横浜(2007, 12. 11-15)
 38. T Wakita. HCV replication in vitro and in vivo, 3rd Pasteur-Areva Course on Blood-Borne Viruses: Hepatitis C Virus, Shanghai, China (Oct 15-18, 2007)
 39. T Wakita, H Aizaki, Critical roles of virion-associated cholesterol and sphingolipids in the viral infectivity, The 7th Awaji International Forum on Infection and Immunity, The Hyogo Prefecture Awaji Yumebutai International Conference Center, (2007 9/1-5)
 40. H Aizaki, M Fukazawa, K Morikawa, H Hara, H Tani, K Hanada, Y Matsuura, M Lai, T Miyamura, T Wakita, T Suzuki, Critical roles of virion-associated cholesterol and sphingolipids in the viral infectivity, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 41. R Fischer, S Gorke, L Lan, S J. Rau, T Wakita, H E. Blum¹, M B. Zeisel, T F. Baumert, Hepatitis C virus replication sensitizes human hepatoma cells to TRAIL-induced apoptosis, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 42. G Mateu, R O. Donis, J Bukh, T Wakita, A Grakoui, Intragenotypic chimeric hepatitis C viruses produce high levels of infectious particles but cause increased cell death, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007,

9. 9-13)
43. D Sir, W-l Chen, T Wakita, T. S. B Yen and J. -H. J Ou, INDUCTION OF AUTOPHAGY BY HEPATITIS C VIRUS VIA ENDOPLASMIC RETICULUM STRESS, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 44. P Podevin, S Lagaye, A Carpentier, L Aoudjehane, M Carrière, S Zaidi, M Dreux, O Scatton, T Wakita, F-L Cosset, F Conti, Y Calmus, A R Rosenberg, Production of infectious hepatitis C virus in primary culture of human adult hepatocytes, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 913)
 45. Murayama A, Date T, Morikawa K, Akazawa D, Ishii K, Wakita T, The important regions for RNA replication and infectious virus particle formation of JFH-1, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 913)
 46. K Murakami, I Shoji, I Hamamoto, T Suzuki, T Miyamura, T Wakita, Virological characterization of HCV JFH-1 strain in B-lymphocytes, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 47. Kato T, Choi Y, Elmowalid G, Sapp R, Furusaka A, Wakita T, Krawczynski K, Liang J, The hepatitis C virus JFH-1 is associated with attenuated infection and low virulence in chimpanzee, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 48. Machida K, Huang J, Wang C-H, Liu H, Kondo Y, Sung V, Wakita T, Lai M, Preferential lymphotropism vs. hepatotropism of different HCV isolates established through infectious full-length viral RNA studies, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 49. Shimoike T, Mckenna SA, Lindhout DA, Wakita T, Puglisi JD, The HCV IRES is a potent activator of PKR but resistant to eIF2 phosphorylation, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 50. Masaki T, Suzuki R, Miyamura T, Wakita T, Suzuki T, Analysis of NS5A region for hepatitis C virus particle production, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 51. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Trono D, Kato N, DNA damage sensors, ATM and Chk2, are required for hepatitis C virus RNA replication, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 52. Fukasawa M, Nitahara-Kasahara Y, Shinki-Ouchi F, Sato S, Suzuki T, Murakami K, Wakita T, Hanada K, Miyamura T, Nishijima M, Cellular vimentin affects the protein level of hepatitis C virus core protein and the activity of hepatitis C virus production in cultured cells, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 53. Sakamoto N, Sekine-Osajima Y, Mishima K, Nakagawa M, Tasaka M, Nishimura-Sakurai Y, Yamamoto M, Onui Y, Sudo G, Itsui Y, Wakita T, Watanabe M, Development of plaque-forming assays for hepatitis C virus and isolation of mutants with enhanced cytopathogenicity and replication capacity, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
 54. Takahashi H, Akazawa D, Omi N, Nakamura N, Mochizuki H, Suzuki T, Wakita T, An adaptive mutation in E2 glycoprotein allow an efficient production of HCV particles with epitope-tagged envelope, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 913)

55. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF. Scavenger receptor BI is required for an entry step closely linked to CD81, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
56. Akazawa D, Takahashi H, Omi N, Date T, Morikawa K, Murayama A, Nakamura N, Mochizuki H, Wakita T, Characterization of infectious HCV particles produced from various liver-derived cell lines, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
57. Isogai M, Uenishi R, Hase S, Suzuki R, Suzuki T, Wakita T, Takebe Y, Identification of new class of HCV inhibitors targeted to the entry or late stages in HCV replication cycle using newly developed JFH-1 based infectivity/replication assay, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
58. Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouille Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C, Robust production of infectious viral particles in Huh-7 cells by introducing mutations in HCV structural proteins, 14th International Meeting on Hepatitis C and Related Viruses. Glasgow, Scotland, UK (2007, 9. 9-13)
59. P Podevin, S Lagaye, A Carpentier, L Aoudjehane, M Carrière, S Zaïdi, JF Meritet, M Dreux, O Scatton, T Wakita, F-L Cosset, F Conti, A R Rosenberg, Y Calmus, Production of infectious hepatitis C virus in primary culture of human adult hepatocytes, The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA (November 2-6, 2007)
60. Masaki Wakita T, Analysis of NS5A region important for hepatitis C virus particle production, The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA (November 2-6, 2007)
61. Hussein H. Aly, Makoto Hijikata, Kunitada Shimotohno: A novel culture system for HCV infection and replication. 14th International symposium on hepatitis C Virus & related viruses. Glasgow UK, Sept, 2007
62. Kaku Goto, Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kunitada Shimotohno: The emergence of a cyclophilin inhibitor-resistant HCV variant with a mutation in NS5A. 14th International symposium on hepatitis C Virus & related viruses. Glasgow UK, Sept, 2007
63. 村上善基、土方誠、下遠野邦忠：マイクロ RNA を用いた新規 HCV 治療法の確立、第 66 回日本癌学会学術総会、平成 19 年 9 月、横浜 2007
64. Tanaka Y, Yamaguchi T, Segawa M, Sugiyama M, Hijikata M, Shimotohno K, Mizokami M. In vitro infection of immortalized human hepatocytes by hepatitis B virus and its application to anti-viral treatment. 58th Annual Meeting of the American Association for the Study of Liver Diseases. November 2-6 2007. Boston.
65. Tanaka Y, Yamaguchi T, Segawa M, Sugiyama M, Hijikata M, Shimotohno K, Mizokami M. A novel three-dimensional long-term culture system of human hepatocytes for hepatitis B virus infection. 2007 International HBV meeting: The Molecular Biology of Hepatitis B Viruses. September 16-20 2007. Rome, Italy.
66. Tanaka Y, Sugiyama M, Takahashi S, Kato T, Shimada T, Sakamoto T, Orito E, Mizokami M. HBV Now in Asia. Difference of HBV genotype in vivo and in vitro. 17th APASL Conference. March 27-30 2007. Kyoto.
67. Tanaka Y, Yamaguchi T, Segawa M, Sugiyama M, Mizokami M. A novel three-dimensional

- long-term culture system of human hepatocytes for HBV infection. 17th APASL Conference. March 27-30 2007. Kyoto.
68. Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. 17th APASL Conference. March 27-30 2007. Kyoto.
69. Shuhei Tagawa, Toru Okamoto, Takayuki Abe, Kohji Moriishi, and Yoshiharu Matsuura: Human butyrate-induced transcript 1 interacts with HCV NS5A and regulates HCV replication. 14th International Meeting on HCV and Related Viruses, Glasgow, September 9-13, 2007.
70. Takayuki Abe, Yuuki Kaname, Xiaoyu Wen, Kohji Moriishi, Tatsuya Kanto, Norio Hayashi, and Yoshiharu Matsuura: Enhancement of IP-10 expression via TLR signaling pathway in cells expressing HCV proteins. 同上。
71. Hideki Tani, Yasumasa Komoda, Chang Kweng Lim¹, Yasumasa Komoda^{1,2}, Itsuki Hamamoto¹, Eiko Matsuo, Kensuke Suzuki, Itsuki Hamamoto, Tetsuo Yamashita, Kohji Moriishi, Eiko Matsuo¹, Kensuke Suzuki^{1,2}, Yoshimi Tsuda¹, Kohji Moriishi¹, Rie Tanigawa^{1,3}, Kazuhito Fujiyama, Tatsuya Kanto, Norio Hayashi, Kohji Moriishi¹, Ania Owsianka, Tatsuo Miyamura⁶, Arvind H. Patel, Michael A. Whitt, and Yoshiharu Matsuura: Cell Tropisms of Pseudotype Vesicular Stomatitis Viruses Bearing Hepatitis C Virus Envelope Glycoproteins Derived from Different Cell Lines. Replication-competent recombinant vesicular stomatitis virus encoding HCV envelope proteins. 同上。
72. Yoshio Mori, Kiyoko Okamoto, Toru Okamoto, Yasumasa Komoda, Masayasu Okochi, Masatoshi Takeda, Tetsuro Suzuki, Kohji Moriishi, and Yoshiharu Matsuura: Intramembrane processing by SPP regulates membrane localization of HCV core protein and viral propagation. 同上。
73. Toru Okamoto, Kohji Moriishi, and Yoshiharu Matsuura: FKBP8 Plays a Crucial Role in the Replication of Hepatitis C Virus, HEP DART 2007, Hawaii, 9-13 December, 2007.
74. 森石恆司、森屋恭爾、村田茂穂、田中啓二、鈴木哲朗、宮村達男、小池和彦、松浦善治: HCV コア蛋白質による脂肪酸合成促進と肝細胞癌発症における PA28 γ の役割: 第 43 回日本肝臓学会総会ワークショップ、東京、5 月 31 日-6 月 1 日, 2007.
75. 田畝修平、岡本 徹、阿部隆之、森 嘉生、森石恆司、松浦善治: C 型肝炎ウイルスゲノム複製に参与する宿主蛋白質 B-ind1 の機能解析: 第 55 回日本ウイルス学会総会、札幌、10 月 21 日-23 日, 2007.
76. 阿部隆之、森石恆司、考藤達哉、林 紀夫、審良静男、松浦善治: C 型肝炎ウイルスによる TLR シグナル伝達経路を介した炎症性ケモカイン IP-10 の過剰産生、同上。
77. 谷 英樹、菰田泰正、鈴木健介、山下哲生、稲田大彦、森石恆司、考藤達哉、林 紀夫、松浦善治: シュードタイプと組換え水疱性口内炎ウイルスを用いた C 型肝炎ウイルスの感染機構の解析、同上。
78. 岡本 徹、森石恆司、松浦善治: C 型肝炎ウイルスゲノム複製における FKBP8 の役割、同上。
79. 森 嘉生、岡本貴世子、岡本 徹、菰田泰正、鈴木哲朗、森石恆司、松浦善治: C 型肝炎ウイルスコア蛋白質のシグナルペプチドペプチダーゼによるプロセッシングの生物学的意義、同上。
80. 山下哲生、森 嘉生、森石恆司、李 天成、宮村達男、武田直和、月原富武、吉村政人、松浦善治: E 型肝炎ウイルス様粒子の結晶化と X 線結晶構造解析、同上。
81. Kohji Moriishi. Critical role of PA28 γ -proteasome pathway in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. 7th Awaji International forum on infection and immunology, Awaji, September 1-5, 2007.
82. Kohji Moriishi. Critical role of REG γ /PA28 γ -proteasome pathway in hepatitis C

- virus-associated steatogenesis and hepatocarcinogenesis, 2007 International RIMD-CVRDC Joint Symposium, Osaka, December 18, 2007.
83. Megumi Tasaka, Naoya Sakamoto, Yoshie Itakura, Mina Nakagawa, Yasuhiro Itsui, Yuko Sekine-Osajima, Yuki Nishimura-Sakurai, Chen-Hsin Chen, Mamoru Watanabe: HCV nonstructural proteins responsible for impairing RIG-I/Cardif-induced interferon responses. APASL May-27-2007, Kyoto, Japan.
 84. Sakamoto N, Nakagawa M, Watanabe M, for the Ochanomizu Liver Conference: Clinical and virological factors that predict outcomes of interferon plus ribavirin combination therapy for HCV infection (APDW2007 Symposium, Oct-18-2007, Kobe, Japan).
 85. 第 43 回日本肝臓学会総会ワークショップ、Bone morphogenetic proein-7 (BMP-7)によるHC増補区抑制効果とinterferon- α との相乗効果の解析、2007年6月1日;肝臓2007; 48 suppl (1) p27.
 86. Isogai, M., Uenishi, R., Hase, S., Suzuki, R., Suzuki, T., Wakita, T., and Takebe, Y. Identification of new class of HCV inhibitors targeting to the entry or late stages in HCV replication cycle using newly developed JFH-1-based infectivity/replication assay. HCV 2007 (Sept.9-13, 2007, Glasgow, UK).
 87. Takebe, Y. Identification of novel antiviral small molecule compounds that are likely to block early processes in HCV replication cycle. 2nd Hepatitis C, resistance and new compounds workshop (Oct 31-Nov 1, 2007, Boston)
 88. Uenishi, R., Nohtomi, K., Hase, S., Suzuki, R., Suzuki, T., and Wakita, T., and Takebe, Y. Identification of new class of HCV inhibitors using newly developed JFH-1-based infectivity/replication assay. 第7回あわじしま感染症・免疫フォーラム (Sept.1-5, 2007, 淡路島)
 89. 武部豊、上西理恵、納富香子、長谷彩希、鈴木哲朗、脇田隆字. 感染性HCVクローンJFH-1を用いた感染・増殖アッセイに基づくスクリーニングによる新規標的をもつHCV阻害剤の同定とその解析. 第55回日本ウイルス学会 (2007.10.20-23, 札幌)
 90. 上西理恵、納富香子、長谷彩希、鈴木哲朗、鈴木亮介、脇田隆字、武部豊. 新規阻害剤探索のためのHCV感染・増殖アッセイ系の樹立とその評価. 第55回日本ウイルス学会学術集会総会 (2007.10.20-23. 札幌)
 91. 池田 正徳. HCV RNA複製細胞を用いた抗HCV剤の探索: スタチン剤とインターフェロン併用の有用性を中心として. 第80回日本薬理学会年会, 名古屋, 2007年3月.
 92. 池田正徳、矢野雅彦、阿部健一、有海康雄、團迫浩方、加藤宣之. C型慢性肝炎に対する新しい治療剤候補の培養細胞アッセイ系を用いた探索・評価. 第72回日本インターフェロン・サイトカイン学会学術集会、京都、2007年7月.
 93. 團迫 浩方、池田 正徳、加藤 宣之. Limited suppression of the interferon- β production by hepatitis C virus serine protease in cultured human hepatocytes. 第72回日本インターフェロン・サイトカイン学会学術集会、京都、2007年7月.
 94. 池田 正徳、矢野 雅彦、阿部 健一、有海 康雄、團迫 浩方、加藤 宣之. 新しいC型肝炎治療を目指した培養細胞系の開発. 第17回抗ウイルス化学療法研究会、高松、2007年5月.
 95. 矢野 雅彦、池田 正徳、阿部 健一、團迫 浩方、大越 章吾、青柳 豊、加藤 宣之. 抗HCV剤治療効果の増強が期待される物質の網羅的スクリーニング-C型肝炎に対する治療効果の最大化を目指して- 第43回日本肝臓学会総会、東京、2007年5月.
 96. Kato N, Abe K, Mori K, Ariumi Y, Dansako H, Ikeda M. HCV genetic variability and dynamics in long-term culture of genom-length HCV RNA replicating cells. 第66回日本癌学会学術総会、横浜、2007年10月.
 97. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda

- M, Wakita T, Kato N. DDX3 DEAD box RNA helicase is required for hepatitis C virus RNA replication. 第66回日本癌学会学術総会、横浜、2007年10月.
98. Ikeda M, Yano M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive screening of ordinary nutrients expected to enhance the effects of anti-HCV reagents. 第66回日本癌学会学術総会、横浜、2007年10月.
99. 森 京子、阿部 健一、團迫 浩方、有海 康雄、池田 正徳、加藤 宣之. C型急性肝炎患者血清由来のHCV1bレプリコン複製細胞株の樹立. 第23回中国四国ウイルス研究会、松山、2007年6月.
100. 阿部 健一、池田 正徳、有海 康雄、團迫 浩方、加藤 宣之. 持続的な全長 HCV RNA 複製を維持できる無血清培地を用いた細胞培養系の開発. 第23回中国四国ウイルス研究会、松山、2007年6月.
101. 矢野 雅彦、池田 正徳、阿部 健一、團迫 浩方、大越 章吾、青柳 豊、加藤 宣之. 全長 HCV RNA の複製に影響を与える日常的に摂取する栄養成分の同定および評価. 第23回中国四国ウイルス研究会、松山、2007年6月.
102. 101) Kato N, Abe K, Mori K, Ariumi Y, Dansako H, Ikeda M. HCV genetic variability and dynamics in long-term culture of genome-length HCV RNA-replicating cells. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
103. Abe K, Ikeda M, Ariumi Y, Dansako H, Kato N. Serum-free cell culture system supplemented with lipid-rich albumin for genome-length HCV RNA replication. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
104. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive analysis of the ordinary nutrients as the novel partners of anti-HCV reagents. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
105. Dansako H, Ikeda M, Abe K, Mori K, Ariumi Y, Kato N. A new antiviral assay system using the living cells harboring genome-length HCV RNA. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
106. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Trono D, Kato N. DNA damage sensors, ATM and Chk2, are required for hepatitis C virus RNA. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
107. 加藤 宣之、阿部 健一、森 京子、有海 康雄、團迫 浩方、池田 正徳. 全長 HCV RNA 複製細胞の長期培養により生じる HCV の遺伝的多様性. 第55回日本ウイルス学会学術集会、札幌、2007年10月.
108. 團迫 浩方、池田 正徳、阿部 健一、森 京子、有海 康雄、加藤 宣之. 全長 HCV-RNA の複製 レベルを指標として生細胞のままアッセイできる新しい抗ウイルス剤評価システム. 第5回日本ウイルス学会学術集会、札幌、2007年10月.
109. 森 京子、阿部 健一、團迫 浩方、有海 康雄、池田 正徳、加藤 宣之. C型急性肝炎患者血清由来の1b型 HCV レプリコン複製細胞株の樹立. 第55回日本ウイルス学会学術集会、札幌、2007年10月.
110. 矢野 雅彦、池田 正徳、阿部 健一、團迫 浩方、大越 章吾、青柳 豊、加藤 宣之. 日常的に摂取し抗 HCV 効果を有する栄養成分の全長 HCV RNA 複製細胞を用いた網羅的探索. 第55回日本ウイルス学会学術集会、札幌、2007年10月.
111. 110) 有海 康雄、黒木 美沙緒、阿部 健一、團迫 浩方、池田 正徳、脇田 隆字、Didier Trono、加藤 宣之. DNA 損傷センサー ATM と Chk2 は HCV の RNA 複製に必要な宿主因子である. 第55回日本ウイルス学会学術集会、札幌、2007年10月.
112. 111) 有海 康雄、黒木 美沙緒、阿部 健一、團迫 浩方、池田 正徳、脇田 隆字、加藤 宣之. HCV の RNA 複製に必要な宿主因子 DDX3 DEAD box RNA ヘリカーゼ. 第55回日本ウイルス学